BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 2107058)

  • 1. Ovarian endocrine function through five years of continuous treatment with NORPLANT subdermal contraceptive implants.
    Brache V; Alvarez-Sanchez F; Faundes A; Tejada AS; Cochon L
    Contraception; 1990 Feb; 41(2):169-77. PubMed ID: 2107058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ovulatory dysfunction during continuous administration of low-dose levonorgestrel by subdermal implants.
    Faundes A; Brache V; Tejada AS; Cochon L; Alvarez-Sanchez F
    Fertil Steril; 1991 Jul; 56(1):27-31. PubMed ID: 1906017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estradiol plasma levels during long-term treatment with Norplant subdermal implants.
    Croxatto HB; Díaz S; Pavez M; Brandeis A
    Contraception; 1988 Oct; 38(4):465-75. PubMed ID: 3145171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hormonal changes associated with bleeding during low dose progestogen contraception delivered by Norplant subdermal implants.
    Faúndes A; Alvarez-Sanchez F; Brache V; Jimenez E; Tejada AS
    Adv Contracept; 1991 Mar; 7(1):85-94. PubMed ID: 1908178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sonographic assessment of ovarian and endometrial changes during long-term Norplant use and their correlation with hormonal levels.
    Shaaban MM; Segal S; Salem HT; Ghaneimah SA; Khalifa EA; Ahmed AG
    Fertil Steril; 1993 May; 59(5):998-1002. PubMed ID: 8486202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum concentrations of estradiol, progesterone, and levonorgestrel are not determinants of endometrial histology or abnormal bleeding in long-term Norplant implant users.
    Darney PD; Taylor RN; Klaisle C; Bottles K; Zaloudek C
    Contraception; 1996 Feb; 53(2):97-100. PubMed ID: 8838486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of levonorgestrel-releasing intrauterine device on hormonal profile and menstrual pattern after long-term use.
    Xiao B; Zeng T; Wu S; Sun H; Xiao N
    Contraception; 1995 Jun; 51(6):359-65. PubMed ID: 7554977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abnormal endocrine profile among women with confirmed or presumed ovulation during long-term Norplant use.
    Alvarez F; Brache V; Tejada AS; Faúndes A
    Contraception; 1986 Feb; 33(2):111-9. PubMed ID: 3084166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma progesterone levels during long-term treatment with levonorgestrel silastic implants.
    Croxatto HB; Diaz S; Pavez M; Miranda P; Brandeis A
    Acta Endocrinol (Copenh); 1982 Oct; 101(2):307-11. PubMed ID: 6814139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ultrasonographic and endocrine evaluation of ovarian function among Norplant implants users with regular menses.
    Alvarez F; Brache V; Faundes A; Tejada AS; Thevenin F
    Contraception; 1996 Nov; 54(5):275-9. PubMed ID: 8934060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of deliberate omission of Trinordiol or Microgynon on the hypothalamo-pituitary-ovarian axis.
    Smith SK; Kirkman RJ; Arce BB; McNeilly AS; Loudon NB; Baird DT
    Contraception; 1986 Nov; 34(5):513-22. PubMed ID: 3102162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Norplant implants: the mechanism of contraceptive action.
    Segal SJ; Alvarez-Sanchez F; Brache V; Faundes A; Vilja P; Tuohimaa P
    Fertil Steril; 1991 Aug; 56(2):273-7. PubMed ID: 1906407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of transdermal oestradiol on bleeding pattern, hormonal profiles and sex steroid receptor distribution in the endometrium of Norplant users.
    Boonkasemsanti W; Reinprayoon D; Pruksananonda K; Niruttisard S; Triratanachat S; Leepipatpaiboon S; Wannakrairot P
    Hum Reprod; 1996 Oct; 11 Suppl 2():115-23. PubMed ID: 8982753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mode of action of dl-norgestrel and ethinylestradiol combination in postcoital contraception. II. Effect of postovulatory administration on ovarian function and endometrium.
    Ling WY; Wrixon W; Zayid I; Acorn T; Popat R; Wilson E
    Fertil Steril; 1983 Mar; 39(3):292-7. PubMed ID: 6402387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immediate postpartum insertion of the norplant contraceptive device.
    Molland JR; Morehead DB; Baldwin DM; Castracane VD; Lasley B; Bergquist CA
    Fertil Steril; 1996 Jul; 66(1):43-8. PubMed ID: 8752609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endometrial angiogenic response in Norplant users.
    Subakir SB; Hadisaputra W; Handoyo AE; Affandi B
    Hum Reprod; 1996 Oct; 11 Suppl 2():51-5. PubMed ID: 8982746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemical staining of von Willebrand factor in endometrium of women during the first year of Norplant implants use.
    Au CL; Affandi B; Rogers PA
    Contraception; 1994 Nov; 50(5):477-89. PubMed ID: 7859456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hormonal consequences of missing the pill during the first two days of three consecutive artificial cycles.
    Landgren BM; Diczfalusy E
    Contraception; 1984 May; 29(5):437-46. PubMed ID: 6430642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of levonorgestrel contraceptive implants, Norplant, on blood coagulation.
    Shaaban MM; Elwan SI; el-Kabsh MY; Farghaly SA; Thabet N
    Contraception; 1984 Nov; 30(5):421-30. PubMed ID: 6440738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced endothelial cell migratory signal production by endometrial explants from women using Norplant contraception.
    Subakir SB; Hadisaputra W; Siregar B; Irawati D; Santoso DI; Cornain S; Affandi B
    Hum Reprod; 1995 Oct; 10(10):2579-83. PubMed ID: 8567774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.